AMGN
AMGEN INCB7215-min delayed · EOD close391.27 −0.48% downas of 2026-09-09mkt cap $212B
Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0000318154
Quality score
72/100
B
Growth74
Business quality92
missing: grossMargin
Financial healthno data
missing: debtToEquity, cashToLiabilities
Valuation48
Computed from filed fundamentals against fixed reference bands. Not a recommendation, and not a peer percentile.
The read
Solid, with a soft spot
Highly uneven
Strongest on business quality (92), weakest on valuation (48). The composite is the mean of the sub-scores that could be computed. 3 inputs were unavailable in the filings, so the score reflects what was reported.
Revenue growth
14.0%
year over year
Earnings growth
113.8%
year over year